Hepatoprotective effect of isonicotinoylhydrazone SH7 against chronic isoniazid toxicity

Pharmazie

Volumn 60, Issue 2, 2005, Pages 138-141

  Georgieva, N ^a   Gadjeva, V ^b   Tolekova, A ^b   Dimitrov, D ^a  

^a TRAKIA UNIVERSITY   (Bulgaria)

^b TRAKIA UNIVERSITY   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DICHLOROSALICYLALDEHYDE ISONICOTINOYL HYDRAZONE; ANTIOXIDANT; CATALASE; ISONIAZID; ISONIAZID DERIVATIVE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER HOMOGENATE; LIVER INJURY; LIVER PROTECTION; MOUSE; NONHUMAN;

ANIMALS; ANTITUBERCULAR AGENTS; CATALASE; HEPATITIS, TOXIC; ISONIAZID; LIPID PEROXIDATION; LIVER; MALONDIALDEHYDE; MICE; SUPEROXIDE DISMUTASE;

EID: 14244258185     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Albano E, Tomasi A (1987) Spin trapping of free radical intermediates prodused during the metabolism of isoniazid and iproniazid in isolated hepatocytes. Biochem Pharmacol 36: 2913-2920.
2. Attri S, Rana SV, Vaiphei K, Kattyal R, Sodhi CP, Kanwar S, Singh K (2001) Protective effect of W-acetylcysteine in isoniazid indused hepatic injury in growing rats. Indian J Exp Biol 39: 436-440.
3. Beers R, Sizer T (1952) Spectrophotometric metod for measuring the breakdawn of hydrogenperoxide by catalase. J Biol Chem 195: 133-138.
4. Buss JL, Neuzil J, Ponka P (2002) The role of oxidative stress in the toxicity of piridoxal isonicotinoyl hidrazone. Biochemical Society Transaction 30: 755-757.
5. Black M, Mitchell J, Zimmerman N, Ishate KG, Epler G (1975) Isoniazid-assotiated hepatitis in 114 patients. Gastroenterology 69: 289-302.
6. Byrd R, Nelson R (1972) Isoniazid toxicity. J Amer Med Assoc 220: 1471-1473.
7. Chauhan, R., Mande SC (2001) Characterization of the Mycobacterium tuberculosis H37Rv alkylhydroperoxidase AhpC points to the importance of ionic interaction in oligomerization and activity. Biochem J 354: 209-215.
8. De Logu A, Onnis V, Saddi B, Congiu C, Schivo ML, Cocco MT (2002) Activity of new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother 49: 275-282.
9. Farest L, Glassroth JL, Suider DE (1977) Isoniazid related hepatotoxiticy. Ann Inter Med 86: 114-115.
10. Georgieva N, Gadjeva V (2002) Isonicotinoylhydrazone analogs of isoniazid: relationship between superoxide scavenging and tuberculostatic activities. Biochemistry (Moscow) 67: 588-591.
11. Geran RS, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 13: 1-87.
12. Lilie RD (1965) Histopathologic technique and practical histochemistry. McGraw Hill, London, p. 375.
13. Oswelier GD (1996) Toxicology of Liver and Biliary System. In: Toxicology, Williams & Wilkins, Iowa State, USA, p. 87-95.
14. Plaser ZA, Cushman LL, Jonson BC (1966) Estimation of product of lipid peroxidation (malonyl dialdehyde) in Biochemical Systems. Anal Biochem 16: 359-364.
15. Ramaswamy S, Reich R, Dou SJ, Jasperse L, Pan X, Wagner A, Quitugua T, Graviss E (2003) Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 1241-1250.
16. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S (2002) Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 54: 1299-1321.
17. Scharer L, Schmith J (1969) Serum transaminase evaluations and other hepatic abnormalities in patiens receiving isoniazid. Ann Int Med 70: 1113.
18. Skakun NP, SlivkaYun (1992) The correction of the hepatotoxicity of antitubercular preparations with tocopherol acetate and riboxin. Eksp Klin Farmakol 55: 52-54.
19. Snider DE, La Montagne JR (1994) The neglected global tuberculosis problem: a report of the 1992 World Congress on tuberculosis. J Infect Dis 169: 1189-1196.
20. Sodhi CP, Rana SF, Attri S, Mehta S, Vaiphei K, Mehta SK (1998) Oxidative-hepatic injury of isoniazid-rifampicin in yong rats subjected to protein and energy malnutrition. Drug Chem Toxicol 21: 305-317.
21. Sokolova GB, Nikolaev VP, Braude VI, Ziia AV (1989) Drug prophylaxis of liver lesions induced by isoniazid and its metabolites. Probl Tuberk. 5: 36-40. [in russian]
22. Suja V, Latha SS, Shyamala Devi CS (1997) Protective effect of Liv.52 and Liv.100 ayurvedic formulations on lipid peroxidation in rat liver homogenate. An in vitro study. Indian J Exp Biol 35: 50-52.
23. Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34: 497-500.
24. Turkdigan MK, Agaoglu Z, Yener Z, Sekeroglu R, Akkan HA, Avci ME (2001) The role of antioxidant vitamins (C and E), selenium, and N. sativa in the prevention of liver fibrosis and cirrhosis in rabbits new hopes. Dtsch Tierärzte Wochenschr 108: 71-73.
25. Varbanova S, Georgieva N (1993) New isonicotinoylhydrazones with tuberculostatic action. Veterinary Sci. 27: 81-85 [in Bulgarian].
26. Vidal Pla R, de Gracia X, Gallego B, Alguero C, Bravo C (1991) The hepatotoxicity of tuberculosis treatment. Med Clin (Barc) 97: 481-485.
27. Wiid I, van Helden EH, Hon D, Lombard C, van Helden P (1999) Potentation of isoniazid activity against Mycobacterium tuberculosis by melatonin. Antimicrob Agents Chemother 43: 975-977.